nimacimab
Asset
Peripherally restricted antibody acts as a CB1 receptor inverse agonist to promote weight loss.
- Stage
- Phase 2
- Modality
- Antibody
- Target
- Lipid and ceramide metabolism
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets3
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.